Keying Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Keying Zhang has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Weijun Qin
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
45 shared publications - Donghui Han
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
44 shared publications - Tong Lu
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
43 shared publications - Weihong Wen
School of Life Sciences and Technology Northwestern Polytechnical University Xi'an China
43 shared publications - Changhong Shi
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
42 shared publications - Fa Yang
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
42 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- Open Access
- 30 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
rTMS for rapid relief of sleep disorders induced by influenza virus infection: a clinical retrospective study
To explore the effect of repetitive transcranial magnetic stimulation (rTMS) on influenza-induced sleep disorders, verify its adjuvant value, and reveal the "influenza-immune inflammation-abnormal brain function-sleep disorder" pathway, a retrospective cohort study enrolled 55 adults (18-40 years, no comorbidities) with acute influenza (2023-2025, First Affiliated Hospital of Air Force Medical University). They were divided into positive control group (PC, n = 20, conventional treatment) and rTMS group (n = 16, conventional + rTMS: 10 Hz, 1x/day, 20-30 mins, 3000 pulses, 100% motor threshold, 3 days; split into pre-treatment [BT-rTMS] and post-treatment [AT-rTMS] subgroups). Twenty healthy people served as negative controls group (NC). Assessments included polysomnography (PSG), Sleep Disorder-Visual Analog Scale (SD-VAS), functional near-infrared spectroscopy (fNIRS) for frontal oxygenated hemoglobin, and ELISA for 9 blood indicators. Two-sample Mendelian randomization (TSMR), ROC models, and t-tests (P < 0.05) were used. TSMR showed influenza correlated with insomnia (IVW:P = 0.047, 95% OR = 1.001-1.134) and 27 brain structural changes (frontal most affected, n = 10). Serum IgM (IVW:P = 0.048, 95% OR = 1.001-1.193) and neutrophils (IVW:P = 0.003, 95% OR = 1.018-1.089) mediated sleep disorders, linking to SD-VAS and frontal gray matter. Left inferior frontal gyrus and right orbital gyrus were key. BT-rTMS had abnormal sleep (duration/efficiency/stages) vs NC, with higher right orbitofrontal cortex (R-OFC) and left ventrolateral prefrontal cortex (L-VLPFC) oxygenated hemoglobin (P < 0.05). AT-rTMS improved sleep vs PC, with lower R-OFC/L-VLPFC oxygenated hemoglobin (P < 0.05). A 7-indicator ROC model had AUC = 0.8571. rTMS improves influenza-related sleep disorders short-term by inhibiting frontal overactivation (R-OFC, L-VLPFC) and regulating immunity (IgM,neutrophils), offering a safe, rapid new approach for acute influenza sleep management.
- 30 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessrTMS for rapid relief of sleep disorders induced by influenza virus infection: a clinical retrospective study
To explore the effect of repetitive transcranial magnetic stimulation (rTMS) on influenza-induced sleep disorders, verify its adjuvant value, and reveal the "influenza-immune inflammation-abnormal brain function-sleep disorder" pathway, a retrospective cohort study enrolled 55 adults (18-40 years, no comorbidities) with acute influenza (2023-2025, First Affiliated Hospital of Air Force Medical University). They were divided into positive control group (PC, n = 20, conventional treatment) and rTMS group (n = 16, conventional + rTMS: 10 Hz, 1x/day, 20-30 mins, 3000 pulses, 100% motor threshold, 3 days; split into pre-treatment [BT-rTMS] and post-treatment [AT-rTMS] subgroups). Twenty healthy people served as negative controls group (NC). Assessments included polysomnography (PSG), Sleep Disorder-Visual Analog Scale (SD-VAS), functional near-infrared spectroscopy (fNIRS) for frontal oxygenated hemoglobin, and ELISA for 9 blood indicators. Two-sample Mendelian randomization (TSMR), ROC models, and t-tests (P < 0.05) were used. TSMR showed influenza correlated with insomnia (IVW:P = 0.047, 95% OR = 1.001-1.134) and 27 brain structural changes (frontal most affected, n = 10). Serum IgM (IVW:P = 0.048, 95% OR = 1.001-1.193) and neutrophils (IVW:P = 0.003, 95% OR = 1.018-1.089) mediated sleep disorders, linking to SD-VAS and frontal gray matter. Left inferior frontal gyrus and right orbital gyrus were key. BT-rTMS had abnormal sleep (duration/efficiency/stages) vs NC, with higher right orbitofrontal cortex (R-OFC) and left ventrolateral prefrontal cortex (L-VLPFC) oxygenated hemoglobin (P < 0.05). AT-rTMS improved sleep vs PC, with lower R-OFC/L-VLPFC oxygenated hemoglobin (P < 0.05). A 7-indicator ROC model had AUC = 0.8571. rTMS improves influenza-related sleep disorders short-term by inhibiting frontal overactivation (R-OFC, L-VLPFC) and regulating immunity (IgM,neutrophils), offering a safe, rapid new approach for acute influenza sleep management.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Expression of LHX2 in NEPC and SCLC
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Expression of LHX2 in NEPC and SCLC